Lab Home | Phone | Search
Center for Nonlinear Studies  Center for Nonlinear Studies
 Home 
 People 
 Current 
 Affiliates 
 Visitors 
 Students 
 Research 
 ICAM-LANL 
 Publications 
 Conferences 
 Workshops 
 Sponsorship 
 Talks 
 Colloquia 
 Colloquia Archive 
 Seminars 
 Postdoc Seminars Archive 
 Quantum Lunch 
 Quantum Lunch Archive 
 CMS Colloquia 
 Q-Mat Seminars 
 Q-Mat Seminars Archive 
 P/T Colloquia 
 Archive 
 Kac Lectures 
 Kac Fellows 
 Dist. Quant. Lecture 
 Ulam Scholar 
 Colloquia 
 
 Jobs 
 Postdocs 
 CNLS Fellowship Application 
 Students 
 Student Program 
 Visitors 
 Description 
 Past Visitors 
 Services 
 General 
 
 History of CNLS 
 
 Maps, Directions 
 CNLS Office 
 T-Division 
 LANL 
 
Wednesday, June 19, 2013
2:00 PM - 3:00 PM
CNLS Conference Room (TA-3, Bldg 1690)

Seminar

Computational models and next generation sequencing technologies to study hepatitis viruses

Fabio Luciani
School of Medical Sciences, University of New South Wales

The first part will be on the application of Next-Generation Sequencing (NGS) as a deep sequencing approach to study viral evolution. NGS has redefined the modus operandi in both human and microbial genetics research, allowing the unprecedented generation of very large sequencing datasets on a short time scale and at affordable costs. We have used this technology to study evolution of viral diversity from the founder virus, and also to inform evolution of immune escape in subjects followed longitudinally. A key challenge in NGS technology is the bioinformatics and statistical analysis of the information generated to ensure high quality in the analyses and interpretation of large, error-prone datasets. The increasing size of the NGS datasets being generated, short read lengths, and significant technical error rates carried with each of the emerging technologies will continue to demand sophisticated and efficient support systems. Here I will discuss current bioinformatics and computational modeling approaches for the analysis of NGS data, with particular focus on hepatitis C (HCV) and B viruses.

In the second part, I will present recent studies on founder virus analysis in HCV. New HCV infections are on average initiated by only 1-3 unique ‘founder’ variants. This reduction in genetic diversity may be a potential vulnerable period in HCV infection and offer a new vaccine strategy for targeting founder variants. However, as yet there has been very little understanding of how rapidly or by what amount these founder viruses evolve. I will present data on the evolution of the HCV founder in response to CD8+ T cell driven pressure in both resolving and persistent infections. These data suggest that the HCV founder virus has a rapid turnover and that in HCV, rapid adaptation to cellular immune response is a major driving force in early founder virus evolution.

Host: Elena Giorgi